Principal Financial Group Inc Nurix Therapeutics, Inc. Transaction History

Principal Financial Group Inc

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 Apr 29, 2024	SELL	$7.77 - $15.66 $9,184 - $18,510	-1,182 Reduced 8.36%	12,953 $190,000
Q4 2023 Feb 07, 2024	SELL	$4.25 - $10.71 $5,933 - $14,951	-1,396 Reduced 8.99%	14,135 $145,000
Q3 2023 Nov 02, 2023	BUY	$7.86 - $10.08 $15,735 - $20,180	2,002 Added 14.8%	15,531 $122,000
Q2 2023 Aug 07, 2023	BUY	$8.7 - $13.28 $6,307 - $9,628	725 Added 5.66%	13,529 $135,000
Q1 2023 May 09, 2023	BUY	$8.56 - $13.26 $15,348 - $23,775	1,793 Added 16.28%	12,804 $113,000
Q4 2022 Feb 09, 2023	BUY	$9.86 - $14.59 $108,568 - $160,650	11,011 New	11,011 $120,000

181

68.1M

78K

53.8K

Ticker NRIX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 47,147,800
Market Cap $1.04B
Description
Nurix Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule therapies for the treatment of cancer and immune disorders. The company develops NX-2127, an orally available Bruton's tyrosine kinase (BTK) degrader for the treatment of relapsed or refractory B-cell malignancies...

Get notified when there are updates to the investment portfolio of Principal Financial Group Inc, based on Form 13F filings with the SEC.

Stay updated on Principal Financial Group Inc with notifications on news.